TerelNewton.com

ALL TRADES

Long is shown below. Short is the mirror: entry below, stop above.
Exit: no fixed target. The trailing stop exits (FAST / NORMAL / SLOW).
Profit lock: +0.5R locked at +1R.
Size: 1 contract.

I. AUTO TAKES THESE

T1 CLASSIC
- Setup: green hammer at the low of the last 7
- Entry: 1 tick above the hammer high, next candle only
- Stop: 1 tick below the hammer low (the tip)
T2 CLASSIC + WICK
- Setup: classic hammer with a small head wick
- Entry: 1 tick above the hammer high, next candle only
- Stop: 1 tick below the tip
T3 BIG BODY
- Setup: big body; the selling was rejected
- Entry: 1 tick above the hammer high, next candle only
- Stop: 1 tick below the tip
T4 BIG BODY + WICK
- Setup: big body with a small head wick
- Entry: 1 tick above the hammer high, next candle only
- Stop: 1 tick below the tip
T5 TALL
- Setup: long tail, tall body
- Entry: 1 tick above the hammer high, next candle only
- Stop: 1 tick below the tip
TMB THOR MARUBOZU
- Setup: marubozu-like candle, at the low only
- Entry: 1 tick above the candle high, next candle only
- Stop: 1 tick below the low
T8 TWIN
- Setup: double bottom; the hammer’s tip matches a candle up to 5 back
- Entry: 1 tick above the signal candle
- Stop: 1 tick below the lower of the two tips
2T1–2T4 SECOND CHANCE
- Setup: the signal candle is the 2nd lowest of the last 7
- Entry: 1 tick above the signal candle
- Stop: 1 tick below its tip
⏱ 2m THOR (MTF)
- Setup: a THOR hammer on the 2-minute, traded on the 1-minute chart
- Entry: 1 tick above the 2m hammer’s body top
- Stop: 1 tick below the 2m hammer’s low

II. ASSIST ONLY (AUTO does not take these)

T6 HEAD HAMMER
- Setup: a T4 with a bigger head
- Entry: 1 tick above the hammer high, next candle only
- Stop: 1 tick below the tip
⏱ 5m THOR (MTF)
- Setup: a THOR hammer on the 5-minute
- Entry: 1 tick above the 5m hammer’s body top
- Stop: 1 tick below the 5m hammer’s low

III. OFF BY DEFAULT

T7 LEVEL STACK
TX1–TX5 (red hammer at the low)
T9 OTHER
T10 DOJI
R1 RED CLASSIC
BH BELTHOLD
B BREAKOUT
B.R BREAK & RETEST
⚡ THOR → B
All 🧪 boosters

IV. GATES (every one must pass before AUTO trades)

Win %: at least 55 %, from at least 10 past trades
Difficulty: 50 or less
Hours: 8:00–16:00 ET (Asia off; earlier candles are labelled for study only)
MIN SIZE: NQ 12 · YM 15 · ES 3.5
EXHAUSTION: NQ 20 · YM 25 · ES 5
Location: low (high for shorts) of the last 7
AUTO = THOR ONLY: on

V. STOP OPTIONS (THOR SCORE panel › STOP)

TIP −1 tick (default)
MID-CANDLE
MID-WICK

Finding the Sweet Spot: 38-slide outline

PART 1: Thu Nov 5 · 15 min

Title: Finding the Sweet Spot: Evidence-Based Cannabinoid Dosing for Cancer Pain · Newton, MD · Session B, Rm 334
Disclosures: Trulieve FL Med Dir (equity) · book royalties · speaker/educator · no external funding · generic product names
Goals (5): tell apart low/mod/high THC doses · relate dose to relief + AEs · apply start low, go slow · compare THC vs 1:1 vs CBD · name evidence gaps
Roadmap: 5 chevrons: Integrated care → Evidence → Dose math → Cases → Who benefits; roman numerals II–X with minutes; bookends I and XI
II Integrated care: cannabis = top layer. Layers: treat cause (XRT 8 Gy), meds (opioids/adjuvants), procedures (CPN, IT pump, VA), rehab, cannabinoids. >50% have pain; ASCO 2024: not enough evidence
III Dose evidence: bands low <15, med 15–30, high >30 mg/d. Table: Portenoy, Johnson, Lichtman, Hardy, Zylla. More THC ≠ more relief
IV Routes/AEs: inhaled = mins, lasts 2–4 h; oral = 30–120 min onset, 2–4 h peak, lasts 6–8 h+. AEs: dizziness, sedation, confusion, ↑HR. Sedation adds to opioids/gabapentinoids → Dr. Han
V Dose math: mg = mg/mL × mL · RSO mg/g = %THC × 10 · 1 spray = 2.7 mg THC · MME factors. Ladder: 1–2.5 mg HS → +2.5 q2–3d → 10–20 → ceiling ~30
VI Case A setup: Mrs. D, 72, breast CA bone mets, cannabis-naive, fall risk, oxy 15 MME. Hands: “Start dose? Target?”
Case A course: 1:1 tincture 0.25 mL = 2.5 mg → 0.5 mL = 5 mg. Pain 5→3, sleep 7 h, MME −50%, 60 d/bottle. Goal met = stop going up
VII Case B setup: Mr. T, 58, mCRPC on enzalutamide, daily user (~200 mg THC in flower/d), 90 MME. Hands: “Will 2.5 mg work?”
Case B titration: 5→10→15→20→30→40 mg/d; pain 7→4; MME −25%. Why: tolerance + CYP3A4/2C9 induction. Safeguards: document, PEG, CUDIT-R, no driving
VIII Case C, edibles: Ms. R, 52, CRC. 3 × 10 mg gummies in 75 min = 30 mg → panic, HR 130, vomiting. Restart ¼ gummy (2.5 mg) HS, 1 dose/night
IX Case D setup: Mr. J, 64, pancreatic CA, 105 MME, cannabis-naive. RSO 1 g @ 75% = 750 mg THC. Told “rice grain,” pushed 0.1 mL. Hands: “How much THC?”
Case D math/fix: 0.1 g = 75 mg (30× start, 2.5× ceiling) → ED. Restart: labeled 1:1 at 2.5 mg, or dilute 1 g RSO to 30 mL = 25 mg/mL. Refer for CPN
X Who benefits: chart of 4 pts: 5 / 40 / 30-in-75-min / 75 mg vs 30 mg ceiling. Need less: older, naive, frail. Need more: tolerant, CYP inducers. (optional; cut if long)
XI Takeaways + CTA: 5 takeaways. Research gaps: 1 dose-finding trial ever, no CBD-only/inhaled RCT, opioid sparing never primary. Document mg every visit → Kander
Contact: DrTerelNewton@gmail.com · Terel.Newton@Trulieve.com
Questions? (panel Q&A, moderated by Dr. Jugl at 75–90 min)

PART 2: Fri Nov 6 · ~11 min
20. Title: Is There an Optimal Medical Cannabis Dosage for Cancer Pain? A Focused Analysis of Primary Clinical Studies · Auditorium
21. Disclosures: same as slide 2
22. Goals (4): summarize primary-study evidence · describe dose-response/toxicity by band · recognize evidence limits · define the next dose-finding RCT
23. Roadmap: Question → Methods → Results → Synthesis → In clinic; bookends I and VIII. (CONFIRM talk length)
24. II Background/objective: >50% have pain; use rising; no defined dose. Objective: find best formulation/dose, efficacy, dose-response, AEs
25. III Methods: PubMed through 8/1/26; terms; exclusions; 7 studies (4 RCTs, 1 pilot RCT, 1 single-arm, 1 PK); 3 dose bands
26. IV Results table: Portenoy, Johnson, Lichtman, Hardy, Zylla, Segar, Clarke: design, n, product, mg/d, main result
27. Portenoy detail: n=360; low 2.7–10.8, med 16.2–27, high 29.7–43.2 mg. Primary endpoint negative; low/med beat placebo on secondary analyses; high = more AEs, no added benefit
28. V Synthesis fig: benefit at ≤~30 mg/d; above 30 adds AEs only. Lichtman missed despite being in range; Zylla uncontrolled
29. VI Case E, Ms. K: dronabinol (THC only) 20 mg/d → dysphoria, pain 6. Switch to 1:1, 20 mg THC + 20 mg CBD (≈7.4 sprays) → pain 3. Mirrors Johnson
30. VII Case F, Mr. P: fentanyl 240 + oxy 90 = 330 MME; 27 mg/d cannabis → pain 8→7. Lichtman: cannabinoids work better earlier, at lower MME. Refer for IT pump
31. VIII Limitations: only 7 studies, mixed designs · primary endpoints mostly negative · products vary · opioid sparing uncontrolled · PubMed only, 1 reviewer · means hide individuals
32. Conclusions: abstract conclusion, word for word. In clinic read as “≤~30 mg/d”; evidence thin = reason to study, not to stop
33. CTA (next trial): RCT: placebo vs 1:1 ≤10 vs 1:1 ≤30 mg/d; stratify by MME + CYP inducers; primary ≥30% relief; MME secondary; plasma levels. Asks: clinicians, MEMORY registry, partners
34. Contact: both emails
35. Questions?

BACKUP
36. Case G, Mrs. B, 81: 10 mg/d → drowsy, near-fall, no benefit → stop. Mirrors Hardy
37. Ms. L: unregulated gummies + vape; only ~1 in 6 edibles labeled accurately (Vandrey 2015) → restart 2.5–5 mg labeled; CBD may raise palbociclib levels
38. References: 12 citations; VERIFY Hardy, Segar, Clarke

Page updated

Google Sites

Report abuse